Mesoblast Limited: financial statements

MESONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$10.89

November 20, 2026Market cap $1.4B

What Ploutos Investor adds for Mesoblast

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 11 fiscal years, from FY2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2024–FY2026 fiscal years

Click a line to see it on the chart.

Revenue

LineFY2024FY2025FY2026Average a year
Revenue $5.9M$17M$120M
Cost of revenue $0$5.1M$17M
Gross profit $5.9M$12M$104M
Operating income -$88M-$102M-$57M
Net income -$88M-$102M-$58M
Earnings per share -$0.89-$0.85–
Earnings per share, basic -$0.89-$0.85–
Margins
Gross margin 100.0%70.2%86.1%
Operating margin -1,493.5%-592.0%-47.3%
Net margin -1,490.3%-593.9%-47.8%

Financial statements

MESO's revenue, profits and cash flows from FY2016 to FY2023, 8 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Per-share figures are per quoted ADS, which stands for 10 of the company's ordinary shares; the filings count per ordinary share.

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

Other than debt, no claim large enough to list ranks ahead of the shares.

From the balance sheet of June 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 20, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Mesoblast's filings show?

These are Mesoblast's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MESO's financials

Didn't find what you were looking for?

Ask us
How much revenue did MESO have in FY2026?

Mesoblast had revenue of $120M and net income of -$58M in fiscal FY2026, a net margin of -47.8%.

How much debt does MESO have?

On June 30, 2026 Mesoblast had total assets of $773M, debt of $119M and shareholders' equity of $568M.

How much free cash flow does MESO have?

In fiscal FY2026 Mesoblast had cash from operations of -$44M and spent $833.0K on capital expenditure, leaving -$45M of free cash flow.

Where are the figures from?

From Mesoblast Limited's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.